Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

May 10, 2024

MAXIM GROUP LLC

300 Park Avenue, 16th Floor
New York, New York 10022

 

May 10, 2024

 

 

VIA EDGAR CORRESPONDENCE

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549

 

Re: Aethlon Medical, Inc.
    Registration Statement on Form S-1, as amended
    File No. 333-278188

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the underwriter, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 9:00 a.m., Eastern time, on Tuesday, May 14, 2024, or as soon thereafter as practicable.

 

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated April 25, 2024 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 

The undersigned, as underwriter, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. If you require any additional information with respect to this letter, please contact M. Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

 

 

 

Very truly yours,

 

 

MAXIM GROUP LLC

 

 

By: /s/ Ritesh M. Veera                        
Ritesh M. Veera
Co-Head of Investment Banking

 

cc: M. Ali Panjwani, Esq.
  Pryor Cashman LLP